Brattain M - Search Results

1

Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer.

Malik SN, Brattain M, Ghosh PM, Troyer DA, Prihoda T, Bedolla R, Kreisberg JI. Malik SN, et al. Among authors: brattain m. Clin Cancer Res. 2002 Apr;8(4):1168-71. Clin Cancer Res. 2002. PMID: 11948129

2

Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients.

Malik SN, Siu LL, Rowinsky EK, deGraffenried L, Hammond LA, Rizzo J, Bacus S, Brattain MG, Kreisberg JI, Hidalgo M. Malik SN, et al. Among authors: brattain mg. Clin Cancer Res. 2003 Jul;9(7):2478-86. Clin Cancer Res. 2003. PMID: 12855621

3

Extracellular domain of TGFbeta type III receptor inhibits angiogenesis and tumor growth in human cancer cells.

Bandyopadhyay A, Zhu Y, Malik SN, Kreisberg J, Brattain MG, Sprague EA, Luo J, López-Casillas F, Sun LZ. Bandyopadhyay A, et al. Oncogene. 2002 May 16;21(22):3541-51. doi: 10.1038/sj.onc.1205439. Oncogene. 2002. PMID: 12032856

4

Immunohistochemical determination of EGFR-tyrosine kinase inhibition in clinical samples.

Malik SN, Bedolla RG, Hidalgo M, Brattain MG, Kreisberg JI. Malik SN, et al. Among authors: brattain mg. Methods Mol Med. 2003;85:135-40. doi: 10.1385/1-59259-380-1:135. Methods Mol Med. 2003. PMID: 12710204 Review. No abstract available.

5

Autocrine-mediated ErbB-2 kinase activation of STAT3 is required for growth factor independence of pancreatic cancer cell lines.

DeArmond D, Brattain MG, Jessup JM, Kreisberg J, Malik S, Zhao S, Freeman JW. DeArmond D, et al. Oncogene. 2003 Oct 30;22(49):7781-95. doi: 10.1038/sj.onc.1206966. Oncogene. 2003. PMID: 14586404

6

A novel mechanism of resistance to epidermal growth factor receptor antagonism in vivo.

Rajput A, Koterba AP, Kreisberg JI, Foster JM, Willson JK, Brattain MG. Rajput A, et al. Among authors: brattain mg. Cancer Res. 2007 Jan 15;67(2):665-73. doi: 10.1158/0008-5472.CAN-06-2773. Cancer Res. 2007. PMID: 17234777

7

Phosphorylation and nuclear exclusion of the forkhead transcription factor FKHR after epidermal growth factor treatment in human breast cancer cells.

Jackson JG, Kreisberg JI, Koterba AP, Yee D, Brattain MG. Jackson JG, et al. Among authors: brattain mg. Oncogene. 2000 Sep 21;19(40):4574-81. doi: 10.1038/sj.onc.1203825. Oncogene. 2000. PMID: 11030146

8

Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects.

Jackson JG, St Clair P, Sliwkowski MX, Brattain MG. Jackson JG, et al. Cancer Res. 2004 Apr 1;64(7):2601-9. doi: 10.1158/0008-5472.can-03-3106. Cancer Res. 2004. PMID: 15059917

9

Differences in sensitivity of biological functions mediated by epidermal growth factor receptor activation with respect to endogenous and exogenous ligands.

Sawhney RS, Zhou GH, Humphrey LE, Ghosh P, Kreisberg JI, Brattain MG. Sawhney RS, et al. J Biol Chem. 2002 Jan 4;277(1):75-86. doi: 10.1074/jbc.M103268200. Epub 2001 Oct 29. J Biol Chem. 2002. PMID: 11684674 Free article.

10

Studies on human hyperplastic prostates maintained in organ culture.

Kreisberg JI, Brattain MG, Pretlow TG 2nd. Kreisberg JI, et al. Among authors: brattain mg. Invest Urol. 1977 Nov;15(3):252-5. Invest Urol. 1977. PMID: 73529

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

217 results

Search Page

Filters